Avantor, Inc. (AVTR) Form 8-K — Oct 28, 2026
Avantor reported Q3 2026 net sales of $1,698.3 million, up 4.6% reported and 5.2% organic, exceeding management's expectations and marking a return to year-over-year growth. GAAP net income swung to $203.4 million from a $711.8 million loss in Q3 2025, which had included a $785 million goodwill impairment; adjusted EPS was flat at $0.22. The company raised its FY2026 guidance, lifting organic revenue growth to +0.75%-+1.25% and free cash flow to $525M-$550M. VWR Distribution & Services organic growth accelerated to 5.8%, while Bioscience & Medtech Products returned to organic growth at 3.6%.
Key figures
- Eps
- GAAP diluted $0.30; adjusted $0.22
- Revenue
- 1698300000
- Guidance
- FY2026: organic revenue growth +0.75% to +1.25% (raised from -0.5% to +0.5%); adjusted EPS $0.81-$0.83 (raised from $0.80-$0.83); free cash flow $525M-$550M (raised from $500M-$550M)
- Net Income
- 203400000
- Total Debt
- 3699700000
- Revenue Yoy
- 4.6% reported, 5.2% organic
- Cash Position
- 464300000
- Free cash flow
- $156.2M
- Adjusted ebitda
- $256.9M, 15.1% margin
- Gaap net leverage
- 9.6x
- Vwr segment sales
- $1,233.8M, +5.0% reported / +5.8% organic
- Adjusted net income
- $146.4M
- Operating cash flow
- $195.1M
- Adjusted net leverage
- 3.1x
- Bioscience segment sales
- $464.5M, +3.5% reported / +3.6% organic
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.